ReviewNuclear medicine and molecular imaging2026
Current Status of PSMA-Targeted Agents Based on Small Molecules for Prostate Cancer in Preclinical Studies.
Review in Nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate-specific membrane antigen (PSMA) has emerged as a clinically validated target for the diagnosis and treatment of prostate cancer using radioligand therapy (RLT). Among various PSMA-targeting ligands, urea-based small-molecules have gained limelight due to their favorable pharmacokinetic properties, high tumor penetration and convenient radiolabeling. Current preclinical research focuses on enhancing in vivo efficacy by optimizing ligand design, radionuclide selection, and improved pharmacokinetics. To reduce off-target toxicity in organs and enhance tumor accumulation, strategies involving the incorporation of albumin-binding moieties or linker modifications have been explored. Various studies have focused on PSMA-targeted therapies labeled with radionuclides, including β emitters (lutetium-177), α emitters (actinium-225 or astatine-211), and Auger electron emitters (iodine-125), that provide unique DNA damage mechanisms tailored to the tumor size and disease stage. This review summarizes recent approaches of PSMA-targeted small-molecules to optimize therapeutic efficacy while minimizing adverse effects on healthy tissues for RLT of prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.